Abacus Planning Group’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.59M | Sell |
39,735
-302
| -0.8% | -$25.3K | 0.44% | 30 |
|
|
2026
Q1 | $3.21M | Sell |
40,037
-10
| -0% | -$824 | 0.43% | 29 |
|
|
2025
Q4 | $3.41M | Sell |
40,047
-124
| -0.3% | -$10.2K | 0.45% | 31 |
|
|
2025
Q3 | $3.12M | Hold |
40,171
| – | – | 0.43% | 31 |
|
|
2025
Q2 | $3.14M | Sell |
40,171
-24
| -0.1% | -$1.79K | 0.47% | 30 |
|
|
2025
Q1 | $2.91M | Sell |
40,195
-12
| -0% | -$859 | 0.51% | 29 |
|
|
2024
Q4 | $2.98M | Buy |
40,207
+140
| +0.3% | +$9.8K | 0.52% | 28 |
|
|
2024
Q3 | $2.64M | Buy |
40,067
+629
| +2% | +$45.7K | 0.47% | 30 |
|
|
2024
Q2 | $3.64M | Buy |
39,438
+19
| +0% | +$1.68K | 0.71% | 22 |
|
|
2024
Q1 | $3.77M | Hold |
39,419
| – | – | 0.74% | 22 |
|
|
2023
Q4 | $3.01M | Sell |
39,419
-78
| -0.2% | -$5.43K | 0.63% | 25 |
|
|
2023
Q3 | $2.74M | Buy |
39,497
+78
| +0.2% | +$6.27K | 0.67% | 25 |
|
|
2023
Q2 | $3.72M | Sell |
39,419
-425
| -1% | -$36.9K | 0.9% | 18 |
|
|
2023
Q1 | $3.3M | Buy |
39,844
+375
| +1% | +$29.5K | 0.85% | 19 |
|
|
2022
Q4 | $2.94M | Sell |
39,469
-603
| -2% | -$46.5K | 0.81% | 19 |
|
|
2022
Q3 | $3.31M | Hold |
40,072
| – | – | 1% | 18 |
|
|
2022
Q2 | $3.81M | Hold |
40,072
| – | – | 1.12% | 18 |
|
|
2022
Q1 | $4.72M | Hold |
40,072
| – | – | 1.27% | 16 |
|
|
2021
Q4 | $5.19M | Hold |
40,072
| – | – | 1.39% | 16 |
|
|
2021
Q3 | $4.54M | Sell |
40,072
-155
| -0.4% | -$17.7K | 1.44% | 15 |
|
|
2021
Q2 | $4.17M | Sell |
40,227
-1,490
| -4% | -$140K | 1.27% | 15 |
|
|
2021
Q1 | $3.49M | Sell |
41,717
-1,660
| -4% | -$140K | 1.12% | 17 |
|
|
2020
Q4 | $3.96M | Hold |
43,377
| – | – | 1.22% | 15 |
|
|
2020
Q3 | $3.46M | Sell |
43,377
-570
| -1% | -$44.5K | 1.26% | 15 |
|
|
2020
Q2 | $3.04M | Sell |
43,947
-66
| -0.1% | -$4.69K | 1.24% | 15 |
|
|
2020
Q1 | $2.77M | Sell |
44,013
-489
| -1% | -$35.3K | 1.36% | 14 |
|
|
2019
Q4 | $3.46M | Sell |
44,502
-246
| -0.5% | -$19.2K | 1.59% | 9 |
|
|
2019
Q3 | $3.28M | Buy |
44,748
+1,299
| +3% | +$91.3K | 1.63% | 8 |
|
|
2019
Q2 | $2.68M | Sell |
43,449
-2,241
| -5% | -$136K | 1.61% | 10 |
|
|
2019
Q1 | $2.91M | Sell |
45,690
-696
| -2% | -$39.7K | 1.82% | 10 |
|
|
2018
Q4 | $2.37M | Sell |
46,386
-390
| -0.8% | -$19.7K | 1.8% | 11 |
|
|
2018
Q3 | $2.71M | Hold |
46,776
| – | – | 1.82% | 9 |
|
|
2018
Q2 | $2.27M | Sell |
46,776
-1,755
| -4% | -$81.9K | 1.7% | 9 |
|
|
2018
Q1 | $2.26M | Sell |
48,531
-201
| -0.4% | -$8.73K | 1.84% | 10 |
|
|
2017
Q4 | $1.83M | Buy |
+48,732
| New | +$1.79M | 1.86% | 10 |
|
Other funds holding EW
Abacus Planning Group's EW Position: Q2 2026 in Review
Abacus Planning Group reduced its Edwards Lifesciences (EW) stake by 0.75% in Q2 2026, selling an estimated $25.3K and leaving 39,735 shares worth $3.59M. The position accounts for 0.44% of the portfolio, ranked #30.
Abacus Planning Group first reported a position in EW in Q4 2017 and has held it in 35 quarters since. The position peaked at $5.19M in Q4 2021. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Abacus Planning Group held 39,735 shares of Edwards Lifesciences worth $3.59M as of Q2 2026.
- Abacus Planning Group sold 302 Edwards Lifesciences shares in Q2 2026, an estimated $25.3K.
- Edwards Lifesciences made up 0.44% of Abacus Planning Group's portfolio in Q2 2026, its #30 holding.
- Abacus Planning Group first reported a position in Edwards Lifesciences in Q4 2017 and has held it in 35 quarters since.
- Abacus Planning Group's Edwards Lifesciences position peaked at $5.19M in Q4 2021.
- 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Abacus Planning Group's 13F filing for Q2 2026, filed 20 Jul 2026.